Citi Analyst Raises Amgen Target Price to $405 Amid Hold Rating

Citi analyst Geoff Meacham has maintained Amgen (AMGN.US) with a hold rating, adjusting the target price from $345 to $405.

According to TipRanks data, Meacham's past performance is impressive, with a success rate of 58.5% and an average return of 14.8% over the past year.

This means that out of his total ratings, he has successfully predicted the market movement for nearly six in ten times, earning his TipRanks virtual portfolio a positive return on investment.